Johnson & Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine

November 17, 2020 Auto Bot Clinical Trials, Initiates, Johnson & Johnson, P-lll 0

Shots:

  • In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial in collaboration with the UK NIHR
  • The P-lll ENSEMBLE 2 study will evaluate the safety and efficacy of a two-dose regimen of the investigational Janssen vaccine for the prevention of COVID-19 in ~30,000 patients across the globe. The ENSEMBLE and ENSEMBLE 2 trials will run in parallel
  • The two P-III studies follow positive interim results of P-I/IIa study assessing the safety profile and immunogenicity of both a single-dose/ two-dose vaccination

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Philadelphia Inquirer

The post Johnson & Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine first appeared on PharmaShots.